p53 (DO7) Mouse Monoclonal Antibody
Specialties: Anatomic Pathology
Anti-p53 tumor suppressor protein antibody recognizes a 53 kDa phosphoprotein, identified as p53 suppressor gene product. It reacts with the mutant as well as wild type p53.1 Positive nuclear staining with this antibody has been shown to be a factor in breast carcinoma, lung carcinoma, colorectal carcinoma, urothelial carcinoma, and ependymoma.2-8 Anti-p53 positivity has also been used to differentiate uterine serous carcinoma from endometrioid carcinoma, as well as a marker for intratubular germ cell neoplasia.9
- Dabbs DJ. Diagnostic Immunohistochemistry. Third Edition. Saunders. 2006.
- Mayall FG, et al. P-53 immunostaining in the distinction between benign and malignant mesothelial proliferations using formalin-fixed paraffin sections. J Pathol. 1992; 168:377-81.
- Caffo O, et al. Prognostic value of p21(WAF1) and p53 expression in breast carcinoma: an immunohistochemical study in 261 patients with long-term follow-up. Clin Cancer Res. 1996; 2:1591-9.
- Bebenek M, et al. Prospective studies of p53 and c-erbB-2 expression in relation to clinicopathological parameters of human ductal breast cancer in the second stage of clinical advancement. Anticancer Res. 1998; 18:619-23.
- Midulla C, et al. Immunohistochemical expression of p53, nm23-HI, Ki67 and DNA ploidy: correlation with lymph node status and other clinical pathologic parameters in breast cancer. Anticancer Res. 1999; 19:4033-7.
- Van den Berg FM, et al. Detection of p-53 overexpression in routinely paraffin-embedded tissue of human carcinomas using a novel target unmasking fluid. Am J Pathol. 1993; 142:381-5.
- Zen ZS, et al. p53 nuclear overexpression: an independent predictor of survival in lymph node--positive colorectal cancer patients. J Clin Oncol. 1994; 12:2043-50.
- Korshunov A, et al. Immunohistochemical markers for intracranial ependymoma recurrence. An analysis of 88 cases. J Neurol Sci. 2000; 177:72-82.
- Moore BE, et al. p53: a good diagnostic marker for intratubular germ cell neoplasia, unclassified. Appl Immunohistochem Mol Morphol. 2001; 9:203-6.
Specifications
- Reactivity: paraffin
- Visualization: nuclear
- Control: colon carcinoma, breast carcinoma
- Dilution Range: 1:100-1:500*
Package Inserts
IFU
- IVD Rev. 5.0 (CMC45329050)
Have a different keycode?
Click Here
Learn how to obtain your SDS
Ordering Information
For in vitro diagnostic (IVD) use in USA
| 0.1 mL concentrate | 453M-94 |
| 0.5 mL concentrate | 453M-95 |
| 1 mL concentrate | 453M-96 |
| 1 mL predilute | 453M-97 |
| 7 mL predilute | 453M-98 |
For in vitro diagnostic (IVD) use in Canada
| 0.1 mL concentrate | 453M-94 |
| 0.5 mL concentrate | 453M-95 |
| 1 mL concentrate | 453M-96 |
| 1 mL predilute | 453M-97 |
| 7 mL predilute | 453M-98 |
For in vitro diagnostic (IVD) use in Europe
| 0.1 mL concentrate | 453M-94 |
| 0.5 mL concentrate | 453M-95 |
| 1 mL concentrate | 453M-96 |
| 1 mL predilute | 453M-97 |
| 7 mL predilute | 453M-98 |
For research use only (RUO) in Japan
| 0.1 mL concentrate | 453M-94-RUO |
| 0.5 mL concentrate | 453M-95-RUO |
| 1 mL concentrate | 453M-96-RUO |
| 1 mL predilute | 453M-97-RUO |
| 7 mL predilute | 453M-98-RUO |
To request information on this product in additional countries, please click the button below.